J&J Relents on Arkansas Contract Pharmacy Law; AbbVie Exempts MO, MS Covered Entities

Johnson & Johnson building-mounted sign
Johnson & Johnson has ended its contract pharmacy restrictions for Arkansas covered entities.
Johnson & Johnson (J&J) has ended its contract pharmacy restrictions for covered entities in Arkansas, making the New Jersey-based pharmaceutical [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Kedrion Posts 340B Refund Notice; Mylan Issue NDC Changes

Kedrion was one of two drugmakers to issue recent notices to covered entities on a federal government agency website.
Drugmaker Kedrion Biopharma has posted a refund notice to 340B providers, and Mylan notified covered entities of National Drug Code [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Hospital Groups ask Supreme Court to Reverse Ruling that Impacts 340B Eligibility

Hospital groups are urging the Supreme Court to correct what they called HHS' misinterpretation of DSH percentage calculations.
Six national hospital associations recently urged the Supreme Court to correct what they called the Department of Health and Human [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

After Failing To Disclose Conflict of Interest, JAMA Issues Correction to Piece Calling for Increased 340B Oversight and Transparency

JAMA corrected an opinion piece on the 340B program to disclose one author's drug industry ties, shortly after 340B Report reported on the omission.
Two weeks after publishing an opinion piece that called for increased 340B program oversight and provider transparency, JAMA issued a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

HRSA Seeks Public Comment On ADR Process and Required Administrative Load

HRSA is seeking stakeholder comments on the administrative burden of the updated 340B ADR process.
The Health Resources and Services Administration (HRSA) has requested public comment on how petitioners file their initial claims in the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

HRSA Walks Through Hospital Recertification Process Days Before Opening Date

HRSA recently held a webinar for hospitals ahead of their annual 340B recertification period.
The Health Resources and Services Administration (HRSA) held a webinar yesterday to guide hospitals through their annual 340B recertification period, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Two Researchers Call For More 340B Transparency, but JAMA Fails to Disclose Glaring Conflict of Interest

Two researchers authored a recent JAMA opinion piece calling for significant 340B reforms including asking Congress to consider limiting the program to low-income patients.
A recent opinion piece published in JAMA is calling for significant reforms to the 340B program, including more provider transparency, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

HRSA to Host Webinar Tomorrow Ahead of 340B Hospital Recertification Window Opening Aug. 12

The annual 340B hospital recertification period will take place between Aug. 12 and Sept. 9.
With the annual 340B hospital recertification period occurring Aug. 12 to Sept. 9, the Health Resources and Services Administration’s (HRSA’s) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Just Days After Legal Setback, Novartis Exempts Mississippi Providers From Contract Pharmacy Restrictions

Novartis exempted Mississippi 340B providers from its contract pharmacy restrictions following a new state law.
Just days after a federal court in Mississippi denied Novartis’ attempt to block the state’s 340B contract pharmacy access law, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

SK Life Science Posts Refund Notice; Dr. Reddy’s and Pfizer Issue NDC Changes

HRSA recently posted manufacturer notices to covered entities from SK Life Science, Dr. Reddy’s Laboratories, and Pfizer.
SK Life Science issued a refund notice for an epilepsy drug following a 340B price ceiling recalculation. Multiple drug manufacturers [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live